The luteolin ability to halt cell divisions and restricted focal adhesion kinase (FAK) activity are demonstrated to be important aspects in cancer treatment (Kim et al. 2013; Li, Lin, et al. 2017). This evidence concerns the gene PTK2 and cancer.